Health body launches tender for genomic analysis platforms
Tender seeks automated DNA sequencing and molecular profiling systems, highlighting rising investment in advanced genomics across healthcare laboratories.
Tender seeks automated DNA sequencing and molecular profiling systems, highlighting rising investment in advanced genomics across healthcare laboratories.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
ESTAR - Ente di Supporto Tecnico Amministrativo Regionale has gone to market for a broad suite of genomic and molecular diagnostic platforms. The contract notice for Analytical Systems for Genetic Investigations, published on 1st July 2026, aims to establish a convention for automated DNA sequencing, real-time PCR, CGH-array slide scanning instruments and modular oncology profiling systems. The scope points to a coordinated upgrade of genetic investigation capacity across its laboratories, with cancer genomics explicitly in view.
The notice describes a convention for the supply of analytical systems used in genetic investigations. Instead of focusing on a single technology, ESTAR is bundling together several core platforms that underpin modern genomics and molecular diagnostics.
The planned convention covers four main categories of equipment:
Taken together, these systems support a range of genetic and genomic activities. Automated DNA sequencing provides base-level information on genetic material. Real-time PCR is a workhorse method for detecting and quantifying specific nucleic acid targets. CGH-array slide scanners enable array-based comparative genomic analysis, while modular oncology profiling platforms are used to characterise tumours at the molecular level.
Bringing these technologies under a single convention suggests ESTAR wants to rationalise and standardise genetic investigation tools across its network. Rather than separate procurements for each laboratory or platform type, a unified arrangement can help align equipment choices, simplify support and, over time, improve interoperability of workflows and results.
The high-level notice does not spell out the number of lots, contract length or participating sites. But the breadth of the technology categories points to a significant refresh of the genomic and molecular toolkit available to clinicians and laboratory scientists.
The explicit reference to modular systems for molecular profiling in oncology gives this procurement a clear cancer focus alongside broader genetic work. These platforms typically support panels of tumour markers and gene variants that inform diagnosis, prognosis and therapy selection.
Other recent notices show a similar push to strengthen tumour and hereditary disease genomics. In March 2026, A.O. SAN GIUSEPPE MOSCATI issued a contract notice for Supply of NGS Diagnostic Kits, seeking diagnostic kits and consumables for next generation sequencing with high-productivity automatic preparers for a genetics laboratory. That notice focused on the consumable side of high-throughput sequencing, complementing the kind of hardware platforms ESTAR now wants to secure.
In April 2026, Azienda ospedaliera Novara published Analytical Systems for Genetics, a full-service procurement of integrated and automated systems for nucleic acid extraction and genetic variant research, alongside a complete automatic extractor with reagents and consumables. Where Novara concentrated on automating preparation and variant detection workflows, ESTAR’s convention goes further along the chain by explicitly including array scanners and oncology profiling modules.
Sequencing infrastructure is also being expanded. In March 2026, ASST DI CREMONA launched Supply of Sequencing Systems for its laboratories, covering various sequencing platforms and diagnostic solutions for genomic analysis and variant identification. That move underlined the demand for multiple sequencing form factors; ESTAR’s inclusion of automated DNA sequencing within a broader convention fits the same pattern of building a flexible, multi-platform genomic environment.
The genomic push is not limited to diagnostic laboratories. In March 2026, Panepistimiako Geniko Nosokomeio Patron "Panagia i Voitheia" issued Innovative Surgical Systems Procurement, combining fully automated NGS systems with modern 3D ultrasound and advanced guidance systems for neurosurgical applications. That notice shows how next generation sequencing is being woven into wider clinical and interventional programmes, rather than standing alone.
Against this backdrop, ESTAR’s oncology-focused modules are part of a wider shift towards embedding molecular profiling into routine cancer pathways. By pairing those modules with core sequencing, PCR and array infrastructure, the convention could support both solid tumour profiling and other genetic investigations from a shared technological base.
The ESTAR notice sits alongside a growing number of procurements that link genetics and molecular methods with everyday diagnostic work in microbiology, virology and screening.
In January 2026, I.F.O. advertised Genetic Analysis Equipment Supply, covering a machine system and reagents for genetic analysis split into three lots. That procurement illustrated how buyers are now acquiring instruments and reagents together, to guarantee the continuity of genetic workflows.
Molecular virology and screening are also advancing. In February 2026, Azienda Sanitaria Provinciale di Messina - Ufficio Provveditorato launched Service Supply for PCR System, seeking a real-time PCR analytical system and consumables for HPV-DNA determination for Cytopathology and Molecular Biology services. That focus on virus-specific molecular screening echoes ESTAR’s interest in real-time PCR, though ESTAR is taking a broader genetic approach.
In April 2026, ASL 3 - PESCARA issued Service Supply for Molecular Diagnostics, a three-year in-service contract for an analytical system and reagents to support hospital infection surveillance in a microbiology laboratory. That notice shows molecular diagnostics being treated as an integral part of infection control, not a specialised add-on.
ESTAR’s convention, with its mix of sequencing, PCR and array technologies plus oncology profiling, reflects the same convergence. Genetic investigation tools are now expected to serve multiple purposes: from hereditary conditions and oncology, to infectious disease characterisation and broader research needs, often within the same laboratory ecosystem.
The use of a convention by ESTAR mirrors a wider move towards structured, often multi-year arrangements for laboratory technology and supplies. Rather than ad hoc purchases, many buyers are opting for frameworks, rental models or full-service contracts that bundle instruments with reagents, consumables and maintenance.
In February 2026, ASST DEGLI SPEDALI CIVILI DI BRESCIA advertised a large aggregated procedure, Framework Agreement for Laboratory Supplies, to secure single-use and multi-use materials including consumables for chromatography and life sciences equipment. That framework created a central vehicle to support a broad range of laboratory activities.
Service and rental models are also prominent. In June 2026, ASL 4 - TERAMO launched Rental Supply of Diagnostic Systems, a five-year rental arrangement for diagnostic systems, reagents and consumables across multiple lots, including molecular diagnostic platforms. That approach transfers capital costs into operating expenditure and binds suppliers into longer-term service relationships.
At a more comprehensive level, Azienda Sanitaria Provinciale di Siracusa opened an extensive procedure in July 2026 for Analytical Systems Supply for Hospitals, covering a wide array of analytical systems for Clinical Pathology units across several hospital centres. And in July 2026, ASL Roma 5 issued Supply of Laboratory Equipment and Materials, an in-service procurement across eight lots that brings together machine systems, equipment, reagents and consumables for analysis laboratories.
ESTAR’s use of a convention for genetic and oncology systems fits into this pattern of more structured, aggregated buying. While the text provided focuses on instruments, many of the comparable notices explicitly bundle hardware with reagents and consumables. That trend suggests laboratories are looking for stability of supply and vendor accountability across the full lifecycle of tests, not only the initial purchase of analytical platforms.
The current notice gives a clear signal about the technologies ESTAR wants to put in place, but leaves a number of questions open. Future documentation and, eventually, award information will show how the convention is divided into lots, how many suppliers are appointed and whether reagents, consumables and maintenance are included alongside equipment.
It will also be important to see how the oncology profiling modules are specified in relation to the underlying sequencing, PCR and array platforms. The balance between highly targeted tumour panels and broader genetic capabilities will shape how far the new systems support both specialised cancer care and wider genomic services.
For now, the Analytical Systems for Genetic Investigations notice underlines a wider shift: genomic and molecular platforms are becoming core infrastructure for healthcare laboratories. ESTAR’s convention, with its mix of sequencing, PCR, array scanning and oncology profiling, is one more sign that these technologies are moving from niche projects to standard tools within public-sector diagnostics.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.